 |
|
|
| |
Safety Profile of HIV-1 Attachment Inhibitor Prodrug
BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis
|
| |
| |
Reported by Jules Levin
IDWeek 2014
8-12 October 2014, Philadelphia, PA, USA
J Lalezari1, GH Latiff2, C Brinson3, J Echevarría4, S Treviño-Pérez5, JR Bogner6, D Stock7, SR Joshi7, GJ Hanna8, M Lataillade7, for the AI438011 study team
1Quest Clinical Research, San Francisco, CA, USA; 2Maxwell Clinic, Durban, South Africa; 3Central Texas Clinical Research, Austin, TX, USA; 4Hospital Nacional Cayetano Heredia, Lima, Peru; 5Mexico Centre for Clinical Research, Mexico City, Mexico; 6Hospital of the University of Munich, Munich, Germany; 7Bristol-Myers Squibb, Wallingford, CT, USA; 8Bristol-Myers Squibb, Princeton, NJ, USA
IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14) (BMS663068 vs Reyataz)
|
| |
|
|
|
|
|
